BioWorld MedTech

July 23, 2014

Boston Scientific receives PMA for its Rebel Platinum Chromium BMS

Despite the adoption rates of drug-eluting stents (DES), device makers haven't totally abandoned bare metal stents (BMS). One only has to look at Boston Scientific's (Natick, Massachusetts) most recent product approval as evidence. Read More

World in Review: Oraya Therapeutics expanding AMD wet therapy into Europe

FDA releases documents under IMDRF's single audit program

EPs in Europe gain access to new FlexAbility catheter from St. Jude

Daily M&A: Kindred ups its offer for Gentiva to $17.25 a share, subject to 'diligence'

Agreements/Contracts: Christie NHS to join consortium to develop radiotherapy system

Patent Watch: Neodyne Biosciences receives Korean patent for treatment of Keloids

Hit Bits: New security consulting services aim to protect medical device cybersecurity

Briefly noted

Products

People in Places

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...